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Abstract
Background: Autologous chondrocyte implantation (ACI) has been used over the last two decades to treat focal
cartilage lesions aiming to delay or prevent the onset of osteoarthritis; however, some patients do not respond
adequately to the procedure. A number of biomarkers that can forecast the clinical potency of the cells have been
proposed, but evidence for the relationship between in vitro chondrogenic potential and clinical outcomes is
missing. In this study, we explored if the ability of cells to make cartilage in vitro correlates with ACI clinical
outcomes. Additionally, we evaluated previously proposed chondrogenic biomarkers and searched for new
biomarkers in the chondrocyte proteome capable of predicting clinical success or failure after ACI.
Methods: The chondrogenic capacity of chondrocytes derived from 14 different donors was defined based
on proteoglycans staining and visual histological grading of tissues generated using the pellet culture system.
A Lysholm score of 65 two years post-ACI was used as a cut-off to categorise “success” and “failure” clinical
groups. A set of predefined biomarkers were investigated in the chondrogenic and clinical outcomes groups
using flow cytometry and qPCR. High-throughput proteomics of cell lysates was used to search for putative
biomarkers to predict chondrogenesis and clinical outcomes.
Results: Visual histological grading of pellets categorised donors into “high” and “low” chondrogenic groups.
Direct comparison between donor-matched in vitro chondrogenic potential and clinical outcomes revealed no
significant associations. Comparative analyses of selected biomarkers revealed that expression of CD106 and
TGF-β-receptor-3 was enhanced in the low chondrogenic group, while expression of integrin-α1 and integrin-
β1 was significantly upregulated in the high chondrogenic group. Additionally, increased surface expression of
CD166 was observed in the clinical success group, while the gene expression of cartilage oligomeric matrix
protein was downregulated. High throughput proteomics revealed no differentially expressed proteins from
success and failure clinical groups, whereas seven proteins including prolyl-4-hydroxylase 1 were differentially
expressed when comparing chondrogenic groups.
Conclusion: In our limited material, we found no correlation between in vitro cartilage-forming capacity and
clinical outcomes, and argue on the limitations of using the chondrogenic potential of cells or markers for
chondrogenesis as predictors of clinical outcomes.
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Background
Articular cartilage injuries may develop into osteoarthritis
(OA) [1]. However, the management of cartilage lesions in
the synovial joints still represents a weighty clinical chal-
lenge. Since the mid 90’s, autologous chondrocyte im-
plantation (ACI) has been available as a method to
ameliorate these impairing localised cartilage defects [2].
Successful clinical outcomes of ACI have been reported
for up to 20 years [3, 4]. The original technique has expe-
rienced refinements such as the introduction of collagen
membranes to replace periosteum to cover the defect, the
use of characterised chondrocytes to improve the quality
of the repair tissue or the more recently matrix-assisted
chondrocyte implantation (MACI) where the chondro-
cytes are seeded in a collagen matrix before implantation
[5, 6]. The long-term failure rate of the first generation
procedure is in the range between 20 and 40% after 15
years [7, 8], while five-year failure rate of MACI is re-
ported to be 11% [9], mind that the definition of failure is
not directly comparable between studies.
To improve the decision-making process around the
choice of treatment for patients with localised cartilage
defects, it would be of great advantage to have a tool to
identify those likely to obtain an optimal outcome of the
procedure. Some patient characteristics have been iden-
tified, and although the reports are not unanimous, most
agree on patient age, preoperative function scores, previ-
ous surgeries to the index knee and defect location and
age being linked to the surgical outcome [10–12]. Fur-
ther stratification methods have been pursued by trying
to identify biomarkers linked to clinical outcomes from
liquid biopsies. Wright et al. reported that increased
levels of CD14 and ADAMTS-4 in the preoperative syn-
ovial fluid was linked to the poor outcome of the ACI
[13]. Some few other studies have assessed synovial fluid
or serum for biomarkers of cartilage injury treatment
from which limited putative predictive biomarkers have
been identified [14, 15]. Additionally, molecular bio-
markers to predict treatment outcomes have been ex-
plored from the cell sources used in the procedures.
Thus, markers found in monolayer cultures such as col-
lagen type II A1 (COL2A1), aggrecan (ACAN), fibroblast
growth factor receptor 3 (FGFR-3) and bone morpho-
genic protein 2 (BMP-2) have been associated with
cartilage formation in vivo in a murine model [16].
Stenberg et al. performed a global microarray analysis of
surplus cells from ACI and found no links between
clinical outcomes and genes linked to cartilage formation
in vivo [17].
In the past, it has been demonstrated that even after
applying identical isolation and culture conditions, hu-
man chondrocytes from different individuals display
strikingly different in vitro chondrogenic capacity [18,
19]. Based on such findings, researchers have tried to
search for markers that forecast cell chondrogenicity
from in vitro expanded cells, in order to recognise the
quality of the cells from donors and possibly to improve
the quality of the generated tissue [20–23]. However,
evidence to support the relationship between the in vitro
chondrogenic potency of cells before the implantation
and clinical outcomes is lacking. Therefore, it is uncer-
tain whether markers of intrinsic chondrogenic potency
could be used as prognostic and quality measures in
clinical practice.
In this study, we have explored first if the in vitro
chondrogenic potency of leftover cells from ACIs estab-
lished in pellet cultures could be used as a convenient
and reproducible functional bioassay to predict clinical
outcomes. Secondly, we evaluated if previously reported
markers have predictive clinical or chondrogenic value
in our material. Finally, we investigated whole cell lysates
by quantitative high-throughput proteomics to identify
yet unknown molecular biomarkers that can predict
chondrogenesis and clinical outcomes.
Methods
Human materials and cell isolation
Chondrocytes were surplus cells from 14 patients treated
with autologous chondrocyte implantation and were ac-
quired after the written consent of the patients and ap-
proval from the regional ethics committee (REK Nord
2014/920). The isolation protocol has been described
previously [24]. Briefly, the ~ 200 mg cartilage specimens
were kept in 0.9% NaCl for maximum 2 h before min-
cing to ~ 1mm3 pieces and enzymatic digestion for 3–4
h in DMEM/HAM’s F-12 (Cat. no. T 481–50, BioChrom
Labs) containing collagenase XI (Cat. no. C-9407,
Sigma-Aldrich) at a final concentration of 1.25 mg/mL.
Chondrocytes released from matrix were serially ex-
panded in DMEM/HAM’s F-12 supplemented with 10%
human autologous serum until implantation at passage
3. Surplus cells were cryopreserved in DMEM/HAM’s
F-12, 20% foetal bovine serum (FBS; Cat. no. S0115; Bio-
chrom) and 10% dimethyl sulfoxide (DMSO; Cat. no.
D2650, Sigma-Aldrich) until inclusion in the study. After
careful thawing, the chondrocytes were propagated in
high glucose Dulbecco’s Modified Eagle Medium
(DMEM; Cat. no. D5796; Sigma-Aldrich) supplemented
with L-ascorbic acid (62 mg/L) (Cat. no.103033E; BDH
Laboratory), penicillin and streptomycin (1%) (P/S; Cat.
no. P4333; Sigma-Aldrich) and 10% FBS at 37 °C in hu-
midified atmosphere containing 5% CO2. The medium
was changed twice a week and passaged upon reaching
70–80% confluency.
Chondrogenesis and 3D cultures
Chondrogenic potential of dedifferentiated chondrocytes
was achieved by using both hanging-drop and pellet
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culture method. For pellet cultures, ex vivo expanded
chondrocytes were harvested and prepared at a final
concentration of 5 × 104 cells/150 μL per pellet as previ-
ously described [25]. Briefly, 5 × 104 cells/well were
placed in poly-HEMA (Cat. no. P3932; Sigma-Aldrich)
coated conical-bottom 96 well culture plate (Cat. no.
249935; Thermo Scientific) and centrifuged at 1100 g for
10 min to form cell aggregates. For hanging-drops, chon-
drocytes were dispensed as a 40 μL drop containing 2 ×
104 cells/drop on the lid of a Petri dish. Aggregates were
formed by gravitational forces as the drop was hanging
upside down. After 48 h, spheroids from conical-bottom
plates or hanging-drops were collected and cultured on
a 24 well ultra-low attachment cell culture plate (Cat.
no. 3473; Corning) in a serum-free chondrogenic
medium for 21 d at low oxygen (3% O2). The chondro-
genic medium contained high glucose DMEM,
L-ascorbic acid (62 mg/L), P/S (1%), dexamethasone
(1 μg/mL) (Cat. no. PZN-3103491; Galenpharma),
insulin-transferrin-selenium supplement (ITS) (1:1000)
(Cat. no. 354351; BD Biosciences), transforming growth
factor β1 (10 ng/mL) (TGF-β1; Cat. no. 100-21C; Pepro-
tech) and BMP-2 (100 ng/mL) (Cat. no. 120-02C; Pepro-
tech). Half of the chondrogenic medium was replaced
with fresh chondrogenic medium twice a week.
Flow cytometry
Monolayer cultured chondrocytes were harvested and
prepared at passage 3–4 for surface marker expression
by flow cytometry as previously described [25]. Briefly,
chondrocytes were harvested and washed three times
with cold stain buffer (Cat. no. 554656; BD Biosciences),
filtered through a 70 μm cell strainer and prepared on
ice as single-cell suspensions to a final concentration of
< 1 × 106 cells/100 μL and incubated with antibodies at
1:10 dilution for 1 h. Fluorochrome-conjugated anti-
bodies targeting CD44 (Cat. no. 555479), CD106 (Cat.
no. 561679), CD146 (Cat. no. 561013), CD166 (Cat. no.
560903), CD271 (Cat. no. 560927), isotype control PE
Mouse IgG2b (Cat. no. 555743) and isotype control PE
Mouse IgG1 (Cat. no. 555749) were purchased from BD
Biosciences, USA. Samples were analysed using a BD
FACSAria III flow cytometer and FlowJo software (Tree
Star Inc., USA). Data from three donors were presented
as the average of median fluorescence intensity (MFI)
+/− standard error.
Alcian blue staining and Bern score
Metachromatic staining of proteoglycans by Alcian
blue was done as previously described [25]. Spheroids
from pellet cultures (n = 14, diameter ≈ 1 mm) and
hanging-drops (n = 4, diameter ≈ 0.5 mm) were har-
vested at day 21, washed in DPBS and fixed in 4%
formalin overnight. Fixed spheroids were embedded
in 1% agarose and transferred into a paraffin block.
Paraffin-embedded sections (4 μm) were dewaxed and
stained with Alcian blue solution (Cat. no. A5268;
Sigma-Aldrich) for 30 min. Sections were washed for
2 min in distilled water and counterstained with a
Nuclear fast red solution (Cat. no. N3020; Sigma-Al-
drich) for 5 min. Finally, the sections were washed
and dehydrated by a series of ethanol and xylene
wash, before mounting a coverslip with Histokit (Cat.
no. 1025/500; Glaswarenfabrik Karl Hect). Sections
were imaged by bright field light microscopy (Leica
DMI6000B). To quantify the in vitro chondrogenic
potential, a visual semi-quantitative scoring of tissue
sections (Bern score) was applied independently by
three different observers [26]. The chondrogenic po-
tential was classified into two groups according to
histological outcomes: “Group A” with high chondro-
genic potential (Bern score 6–9) and “Group B” with
low chondrogenic potential (Bern score < 6) (Table 1).
Clinical outcomes and score
Clinical outcomes are from the “ACI-C versus AMIC”
study (Clinicaltrials.gov identifier; NCT01458782) where
41 patients in the age of 18–60 years were included and
randomised to either autologous chondrocyte and colla-
gen membrane implantation (ACI-C) or autologous
matrix-induced chondrogenesis (AMIC). The patients
were included and operated in 2011–2014, the ACI-C
procedure was done as previously described [7] and
Chondro-Gide® membranes were used to cover the de-
fect both for ACI-C and AMIC [27]. Lysholm score and
the knee injury and osteoarthritis outcome score
(KOOS) reporting patients’ pain, symptoms and disabil-
ity were recorded at the preoperative stage, one-year and
two-year follow-up and subsequently used to evaluate
patients’ clinical outcomes. We used Lysholm score of
65 at two-year follow up as a cut-off to categorise clinic-
ally success (> 65) and failure (< 65) as suggested by
Knutsen et al. [7]. Furthermore, we evaluated clinical
outcomes by minimal clinically important difference
(MCID), which confers with an increase of 10 points in
the Lysholm score after one year of post-treatment, to
categorise clinically success group [28]. Both approaches
resulted in identical patient allocation in clinical success
and failure groups. Patients’ demographic data, symp-
toms, history, functional score, clinical findings and pain
as indicated on a visual analogue scale (VAS) were re-
corded. Patients’ demographic characteristics, as well as
defect location and size, are summarised in Table 2.
qPCR
Monolayer chondrocytes were harvested at passage 3–6
at the time of establishment of 3D cultures, and RNA
was extracted using the RNeasy Plus Mini Kit (Cat. no.
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74134; Qiagen) according to the manufacturer’s proced-
ure including DNase I treatment. The RNA concentra-
tion was measured using the NanoDrop 2000, and RNA
from 13 donors had sufficient quality to use for selected
markers expression by qPCR. Using the qScript cDNA
Synthesis Kit (Cat. no. 95047; Quanta Biosciences), 285
ng of each sample was transcribed to cDNA. The qPCR
was performed as previously described [29]. The qPCR
included 5 μL PrecisionFAST mastermix (Cat. no.
Precision-FAST-R; PrimerDesign), 0.5 μL hydrolysis
probe (all from Applied Biosystems), 2.5 μL H2O and
2 μL cDNA (diluted to 2 ng/μL) and was run in 96-well
plates (Cat. no. BW-FAST; PrimerDesign) using the Ste-
pOnePlus Real-Time PCR system (Applied Biosystems).
Hydrolysis probes are summarised in Table 3. The gene
for ribosomal protein L13a (RPL13A) was used as the
reference gene, and ΔCq was calculated by subtracting
the gene of interest from the reference gene, making
higher ΔCq reflecting increased gene expression.
Protein extraction and LC-MS/MS analysis
Three donors with extreme scores from each of the
chondrogenic groups and clinical groups were analysed
by LC-MS/MS. Monolayer chondrocytes were harvested
at passage 3–4, and whole protein was extracted using
the TMTsixplex™ Isobaric Mass Tagging Kit (Cat. no.
90064; Thermo Scientific). Briefly, cells were washed 3
times with DPBS and lysed in buffer containing 1% so-
dium deoxycholate (Cat. no. D6750; Sigma-Aldrich) and
100 mM triethylammonium bicarbonate (TEAB). Cell
lysates were incubated with Pierce™ Universal Nuclease
(Cat. no. 88700; Thermo Scientific) at room temperature
for 15 min and centrifuged at 16000 g for 10 min at 4 °C.
The supernatants were collected, and protein concentra-
tion was measured using a DC Protein Assay Kit (Cat.
no. 5000116; Bio-Rad). Samples containing 100 μg/tube
protein were reduced in 5 mM dithiothreitol (Cat. no.
D9779; Sigma-Aldrich) for 30 min at 70 °C and followed
by incubation with 375 mM iodoacetamide for 30 min in
Table 1 Donor characteristics and donor-specific chondrogenic potential of culture expanded chondrocytes in 3D spheroids
Source Age-ranges gender Passage Hanging-drop culture Pellet culture Bern Score
Group A (Bern Score 6–9)
Donor 1 24–55 F 4 + + 8
Donor 2 M 6 + + 7
Donor 3 M 6 – + 8
Donor 4 M 3 + + 7
Donor 5 M 3 – + 7
Donor 6 M 3 – + 7
Donor 7 F 3 – + 6
Donor 8 F 3 + + 6
Group B (Bern Score < 6)
Donor 9 19–53 M 5 – + 5
Donor 10 F 4 – + 4
Donor 11 F 6 – + 4
Donor 12 M 3 – + 3
Donor 13 M 5 – + 3
Donor 14 M 3 – + 2
Table 2 Clinical outcome of patients after two years of ACI.
Lysholm score (65% cutoff) after two years was used to divide






Pre 2 yr Pre 2 yr Pre 2 yr
Success group (> 65% Lysholm)
Donor 1 19–55 M 2.25 40 3 43.5 82.7 55 90
Donor 2 M 3 40 12 68.5 82.1 69 90
Donor 3 M 4.6 50 10 71.4 83.9 56 86
Donor 4 M 9.75 62 10 62.5 76.9 52 83
Donor 5 F 5.2 31 34 78 82.7 64 78
Donor 6 F 3.6 51 14 68.3 73.8 59 74
Donor 7 F 6 48 51 58.3 70.8 57 69
Donor 8 M 21.5 17 4 72.6 84.8 50 69
Donor 9 M 2.4 67 35 38.7 71.4 58 68
Failure group (< 65% Lysholm)
Donor 10 31–52 F 1.82 50 69 32.1 54.8 56 62
Donor 11 M 5 51 37 82.7 52.4 64 56
Donor 12 M 3 30 56 36.3 47.6 56 49
Donor 13 F 3.1 60 73 68.5 47.6 55 47
Donor 14 M 1.2 74 76 44 35.7 41 38
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the dark at room temperature. Samples were precipi-
tated overnight in pre-chilled acetone (Cat. no. 270725;
Sigma-Aldrich) at − 20 °C and collected as dry pellet
after centrifugation at 8000 g for 10 min at 4 °C. Protein
pellets (25 μg) were resuspended in 2M Urea (Cat. no.
U1250; Sigma-Aldrich) with 50 mM TEAB. Proteins
were digested for 6 h with 1:100 (w/w) lysyl endopeptid-
ase (Cat. no. 125–05061; Wako Chemicals). The samples
were further diluted to 1M Urea and digested overnight
by 1:20 (w/w) trypsin (Cat. no. V511A; Promega). Pep-
tides from each sample were labelled with the TMTsix-
plex™ Isobaric Mass Tagging Kit according to the
manufacturer’s protocol.
OMIX C18 tips were used for sample clean-up and
concentration. Peptide mixtures containing 0.1% formic
acid (Cat. no. 28905; Thermo Scientific) were loaded to
a Thermo Fisher Scientific EASY-nLC1000 system and
EASY-Spray column (C18, 2 μm, 100 Å, 50 μm, 50 cm).
Peptides were fractionated using a 2–100% acetonitrile
(Cat. no. 51101; Thermo Scientific) gradient in 0.1% for-
mic acid over 180 min at a flow rate of 250 nL/min. The
separated peptides were analysed using a Thermo
Scientific Q-Exactive mass spectrometer. Data were col-
lected in a data-dependent mode using a Top10 method.
Raw data were processed using MaxQuant (v 1.5.6.0)
with the integrated Andromeda search engine. MS/MS
data were searched against the UniProt human database
from November 2016. A false discovery rate (FDR) of
0.01 was needed to yield a protein identification.
Statistical validation of protein regulation was per-
formed using the Perseus 1.5.6.0 software. All contami-
nants were filtered out, and intensity values were log2-
transformed for subsequent analysis. The log2-trans-
formed intensities were normalised by adjustment. Data
were grouped as group “A (high) and B (low)” for chon-
drogenesis and “success and failure” for clinical out-
comes. Data were then analysed with a minimum of two
valid values in each group. A t-test visualised as a vol-
cano plot was generated to identify potentially regulated
proteins in the chondrogenic and clinical groups by a
permutation-based FDR < 0.05.
Western blots
Three donors from each chondrogenic group were ana-
lysed by western blot. The protein input was 35 μg/lane
in TruPage gels (Cat. no. PCG2004; Sigma-Aldrich). The
protein was separated along with a BLUeye Prestained
Protein Ladder (Cat. no. PM007–0500; Sigma-Aldrich)
and MagicMark™ XP Western Protein Standard Ladder
(Cat. no. LC5602; Novex). Proteins were transferred to a
PVDF membrane, blocked for 2 h in PBS-Tween (0.05%)
buffer containing BSA (2%) and incubated with 0.1 μg/
mL of prolyl 4-hydroxylase 1 antibody (P4HA1; Cat. no.
NB100–57852; Novus Biologicals) overnight at 4 °C. The
membrane was incubated with secondary donkey
anti-goat antibody (Cat. no. HAF109; Novus Biologicals)
for 1 h at room temperature. Finally, a chemilumines-
cence detection solution (Cat. no. 170–5040, BioRad)
was applied to the membrane before acquiring the im-
ages using an ImageQuant LAS 4000 CCD camera.
Beta-actin antibody (Cat. no. AB8227; Abcam) and goat
anti-rabbit antibody (Cat. no. AB6721; Abcam) were
used as loading control and secondary antibody for
beta-actin, respectively. Relative density was assessed
using ImageJ software to compare the chondrogenic
groups.
Statistical analysis
The Bern score between the two chondrogenic groups
was plotted as dot density and analysed using
Mann-Whitney U comparison. Differences in preopera-
tive, one-year and two-year follow-up scores of VAS,
Lysholm and KOOS total between two chondrogenic
groups were studied using Mann-Whitney U compari-
son. Differences in gene expression between the chon-
drogenic groups and clinical groups were analysed using
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nested linear regression and Benjamini-Hochberg
p-value adjustment. Pearson correlation (r) was per-
formed to investigate the relationship between in vitro
chondrogenic potentials and clinical outcomes. The sig-
nificance level for all tests was set to < 0.05.
Results
The donor-specific chondrogenic potential of surplus
chondrocytes in 3D cultures
Chondrocytes from different donors displayed distinct in
vitro chondrogenic potential in 3D cultures (Fig. 1a and
Additional file 1: Figure S1). Pellet cultures were achiev-
able with cells from all donors. Semi-quantitative assess-
ments of constructs by visual histological grading system
(Bern score) allowed the categorisation of all donors into
two groups: “Group A” (8 donors) and “Group B” (6 do-
nors) with high and low chondrogenic characteristics,
respectively (Fig. 1b). Hanging-drop cultures were, on
the other hand, successful in only half of the donors in
group A and none in group B, indicating that the ability
of cells to form cartilage-like micro-tissues by
hanging-drops had a positive correlation with the intrin-
sic in vitro chondrogenic potential in pellets (Table 1).
To exclude the possible influence of passage number in
chondrogenic outcomes, chondrogenesis was evaluated
for some donors across passages 3 to 6. Bern score dem-
onstrated no differences in chondrogenic features in
constructs made by same donor-cells across different
passages. Of importance, investigation of dedifferenti-
ation in 2D culture confirmed that chondrocytes from
all donors were fully dedifferentiated as shown by drastic
reduction of COL2A1 vs COL1A1 gene expression
(Fig. 2). Donor characteristics, summarised in Table 1,
showed that the distribution of age, gender and passage
is comparable between the two chondrogenic groups.
In vitro chondrogenic potential do not predict clinical
outcomes
To explore if the in vitro chondrogenic potency of sur-
plus cells from ACIs could be used as a functional bio-
assay to predict clinical outcomes, we compared VAS,
total KOOS and Lysholm score to the chondrogenic
groups at baseline, one and two-year after ACI surgery.
Patients’ demographic characteristics and defect location
and size are summarised in Table 2 along with the clin-
ical outcomes. Preoperatively, the median VAS score for
patients in chondrogenic groups A and B was 50.50
(interquartile range (IQR) 15.75) and 45 (IQR: 35.75), re-
spectively, in a scale ranging from 0 to 100, with 100
representing worst imaginable pain. Median VAS score
at first-year follow-up for group A and B was 36 (IQR:
35.75) and 12.50 (IQR: 15.75), respectively. At one-year
follow-up, significantly reduced VAS score was observed
in patients from group B compared to group A. At the
two-year follow-up, the median VAS score was 44 and
20.50 in group A (IQR: 57.75) and group B (IQR: 25.75),
respectively (Fig. 3a).
Both KOOS total and Lysholm scores range from 0 to
100, with 100 representing unimpaired knee function.
The median KOOS total preoperatively was 63.30 (IQR:
27.05) and 65.50 (IQR: 36.90), for patients in chondro-
genic groups A and B respectively. At one-year
follow-up, the median KOOS total was significantly in-
creased in group B (78, IQR: 18.13) compared to group
A (54.15, IQR: 26.80). Median KOOS total at the
two-year follow-up was 61.60 and 79.50 for group A and
B, respectively (Fig. 3b). In addition, preoperative median
Lysholm score was 56 (IQR: 3.50) and 57 (IQR: 13.75) in
chondrogenic group A and B, respectively. Like VAS and
KOOS total at the one-year follow-up, the median
Lysholm score in group B (76.50, IQR: 12.25) was sig-
nificantly improved than group A (60, IQR: 30). At the
two-year follow-up, the median Lysholm score was 62.50
(IQR: 35.5) and 73.50 (IQR: 18.25) in group A and B, re-
spectively (Fig. 3c). Of importance, none of the two-year
follow-up scores resulted in significantly different scores
between the two chondrogenic groups. Both 65 cut-off
of Lysholm score and MCID revealed that four donors
from chondrogenic group A fell in the category of clin-
ical failure along with one donor from group B. Remark-
ably, five donors from the low chondrogenic group
(group B) were in the clinical success category (Fig. 3d).
We did not find a significant correlation (r = −.308, p =
0.284) between in vitro chondrogenic potentials and
clinical outcomes.
Comparative expression of selected markers by the
different chondrogenic and clinical outcome groups
Flow cytometry was used to investigate putative surface
markers of clinical outcomes and chondrogenicity (Figs.
4 and 5). We found a significantly higher expression of
CD166 in the clinical success group compared to the
failure group (MFI: 2160+/− 250 vs 730+/− 50) (Fig. 5a).
The surface expression of CD44 was upregulated in the
clinical success group in a near significant way (p =
0.054). Additionally, the expression of CD106 and
CD146 was on average higher in the clinical success
group compared to the clinical failure group (MFI: 1400
+/− 370 vs 500+/− 100 and MFI: 1150+/− 310 vs 500+/−
30, respectively) (Fig. 5a), but the difference did not
reach statistical significance.
When comparing the chondrogenic groups, the sur-
face expression of CD106 (MFI: 2370+/− 160) was sig-
nificantly higher in group B compared to group A (MFI:
1140+/− 160), thus suggesting a negative association
with in vitro chondrogenic potential. We did not see sig-
nificant differences in the surface expression of CD44
and CD166 between the two chondrogenic groups (Fig.
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4a). The surface expression of CD146 was uneven
among donors within the same chondrogenic group, and
the expression was not indicative of chondrogenic po-
tential (Fig. 4a). We also observed very low surface ex-
pression of CD271 in both chondrogenic and clinical
groups (Figs. 4 and 5). Relative gene expression revealed
significant upregulation of integrin-α1 (ITGA1) and
integrin-β1 (ITGB1) in group A compared to group B,
whereas TGF-β-receptor-3 (TGFBR3) expression was
significantly downregulated in group A (Fig. 4b). In the
clinical groups, the expression of cartilage oligomeric
matrix protein (COMP) and ITGB1 were elevated in the
failure group compared to the success group, but the
expression of ITGB1 (p = 0.055) was barely significant
(Fig. 5b). We did not detect significant differences in any
of the studied genes associated with chondrogenic and
clinical outcome categories (Additional file 2: Figure S2
and Additional file 3: Figure S3).
Fig. 1 Chondrogenesis of culture-expanded chondrocytes in 3D pellets propagated in chondrogenic medium. a Representative bright light
microscopy images of histological sections, stained for proteoglycans with Alcian blue and the nuclei counterstained with Sirius red, corresponding to
“Group A” and “Group B” with high and low chondrogenic potential, respectively. b Semi-quantitative analysis representing the histological scoring of
Alcian blue stained 3D pellets demonstrated significant differences between the two groups. Scale bar: 200 μm and significance level, p (**) < 0.005
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An unbiased search of predictive biomarkers for in vitro
chondrogenesis and ACI clinical outcomes by large-scale
proteomics
A total of 2113 proteins were identified in cell extracts of
chondrocytes from donors in the chondrogenic groups, of
which 76 and 66 were classified as cell adhesion molecules
and cell surface receptors, respectively, using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database. In
the cell extracts from chondrocytes of clinical success and
failure groups, 2034 proteins were identified of which 74
and 59 were categorised as cell adhesion molecules and
cell surface receptors, respectively. High throughput
comparative analyses of identified proteins in the two
chondrogenic groups revealed seven proteins significantly
downregulated in group B compared to group A (Fig. 6a
and b). Of relevance, P4HA1 (FDR < 0.01), an enzyme
involved in collagen triple helix formation, was among the
differentially expressed proteins. This outcome was
validated in western blot analyses from all six donors (Fig.
6c). Moreover, we found no differentially expressed pro-
teins when comparing donor cells belonging to the two
clinical outcome groups (Fig. 6d).
Discussion
The main objective of this study was to address the
question if in vitro chondrogenic potential of
donor-matched chondrocytes could predict clinical out-
comes after ACI. We show that histological grading of
pellets following chondrogenesis was not predictive of
the clinical outcome. In an unbiased search for molecu-
lar markers of chondrogenesis, visual histological scoring
of the 3D pellets was linked to the expression of the col-
lagen synthesis enzyme, P4HA1.
It has been demonstrated that histological grading of
pellets by Bern Score correlates significantly with bio-
chemically assessed glycosaminoglycans content [30]. In
line with other studies, we have also observed divergent
in vitro chondrogenic potentials of culture-expanded
chondrocytes from different donors [18, 20]. Due to un-
avoidable circumstances external to the experimental
plan, the chondrocyte cultures included in this study
were not synchronised at the same passage, but from
passage 3–6 when preparing the pellets and RNA ex-
tracts for qPCR. In addition, other authors have pro-
posed that the loss of cartilage phenotypic traits occur
primarily during the first passages, and the cell pheno-
type becomes more stable after passage 3–4 [31]. We
have confirmed by collagen type I/II gene expression
that all donor chondrocytes were equally dedifferentiated
at the start of 3D cultures (Fig. 2). In previous studies,
we have shown that the chondrocytes redifferentiate in
the 3D culture [25, 32]. Furthermore, neither patient’s
age nor gender were associated with high or low in vitro
chondrogenic potential (Table 1). Thus, we argue that
the divergent donor-specific chondrogenic potential is at
least to some degree donor-dependent and not associ-
ated to cell passage or donor demographics, which is in
line with previous publications [18, 20].
Fig. 2 Dedifferentiation of chondrocytes in monolayer culture. Comparison of COL2A1 and COL1A1 gene expression by qPCR in control and
donor cells (n = 14, passage 3–6) in monolayer culture. Control: Freshly isolated OA chondrocytes; ND: Not detected
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The in vitro chondrogenic potential, as assessed by vis-
ual scoring of histological sections of 3D pellet cultures,
was not associated with clinical success or failure two
years after ACI. Earlier studies have proposed cell quality
as one of the multiple parameters that may influence
clinical outcomes after ACI [16, 22, 23]. In these studies,
cell quality was evaluated by expression of cartilage-spe-
cific differentiation markers such as collagen type II and
aggrecan, and other cell surface receptors such as
FGFR3 and CD44. In a more recent study, the predictive
clinical value of the suggested cell quality markers has
been questioned [17]. In line with the later mentioned
study, we did not observe correlations between the in
vitro chondrogenic potency and clinical outcomes. There
exist a number of possible explanations for our findings.
After ex-vivo cell expansion, chondrocytes lose their
phenotypic traits. It has been reported that the dediffer-
entiation of implanted chondrocytes impairs the quality
of repaired tissue [33]. In addition, the process of cell
redifferentiation is not comparable between in vitro and
in vivo conditions. The fate of implanted chondrocytes
after ACI and their contribution to rebuilding the dam-
aged tissue is mostly unknown. Reports in pre-clinical
models show varying proportions of implanted cells in
the repaired tissue, but the majority of these studies in-
dicate that most of the newly formed tissue is primarily
composed of cells migrating to the lesion [34, 35]. Histo-
logically, the repaired tissue after ACI appears predom-
inantly fibro-cartilaginous [36]. However, it has been
suggested that the quality of repair tissue from a histo-
logical point of view, does not always correlate with clin-
ical outcomes [7, 10, 37]. Collectively, these observations
Fig. 3 Comparison of donor-matched chondrogenic potential with clinical outcomes. VAS score (a), KOOS total (b) and Lysholm score (c) were
plotted against chondrogenic Group A and Group B at the preoperative stage, one-year and two-year follow-up after ACI. d Patient distribution
using Lysholm score (cut-off < 65) at two-year follow-up demonstrated clinical success and failure groups and their no significant association
(r = −.308, p = 0.284) with in vitro chondrogenic potentials. Significance level, p (*) < 0.05
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and our results argue that the cell quality and the intrin-
sic chondrogenic capacity of implanted chondrocytes
may not play a major role in the outcomes of the ACI
procedure.
In previous studies aiming at identifying cell surface
receptors that can predict chondrocytes with an im-
proved chondrogenic potential in vitro, CD44, CD151
and CD146 have singled out as positively correlated with
high chondrogenesis as judged by glycosaminoglycans
content [20] or histological evaluation of spheroid cul-
tures [38]. The CD44 protein expression has also been
investigated in a clinical setting where a positive correl-
ation between a clinical knee score at 24 months and
CD44 protein expression in excess chondrocytes after
ACI was found [22]. However, when Stenberg et al. ana-
lysed surplus chondrocytes from ACI, they found no
Fig. 4 Comparison of selected molecular biomarkers between chondrogenic groups. a Surface protein expression of by flow cytometry from
donors with high scores (n = 3; upper panels) and low scores (n = 3; low panels). Red peak represents the isotype control, and blue, orange and
green peak represent expression by each independent donor. Average median fluorescence intensity (MFI) +/− standard error demonstrated
differences in surface marker expression between two groups. b Analysis of selected genes of interest by qPCR revealed their relative expression
in the high (n = 8) and low (n = 5) chondrogenic groups. Plotted values represent each donor, and the error bar represents standard deviation.
Significance level, p (*) < 0.05
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correlation between CD44 gene expression and clinical
outcome after three years [17]. We observed no differ-
ences in expression of CD44 when comparing chondro-
genic groups. When looking at CD44 expression
between the clinical groups, our findings are in line with
Stenberg’s study, revealing no differences between the
success and failure groups (Fig. 5).
We found elevated surface expression of vascular cell
adhesion molecule 1 (CD106) in chondrocytes from do-
nors displaying low chondrogenesis. A previous study re-
ported the expression of CD106 in chondrocytes and
their role as a marker for immunomodulation in in-
flamed joint [39]. However, in an early study from our
group, comparing the chondrogenic potential of stromal
Fig. 5 Comparison of selected molecular biomarkers between clinical groups. a Surface protein expression by flow cytometry from donors of
clinical success (n = 3, upper panels) and failure (n = 3; low panels). Red peak represents the isotype control, and blue, orange and green peak
represent the tested cell surface marker for each donor. Average median fluorescence intensity (MFI) +/− standard error demonstrated differences
in surface marker expression between two groups. b Analysis of selected genes of interest by qPCR revealed their relative expression in the
success (n = 8) and failure (n = 5) groups. Plotted values represent each donor, and the error bar represents standard deviation. Significance level,
p (*) < 0.05 and (**) < 0.005
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cells from different tissue sources, we observed no associ-
ation of CD106 surface expression with the chondrogenic
potential of cells in vitro [25]. Hence, the role of CD106 in
chondrogenesis may require further investigation. Import-
antly, we saw a significant upregulation of CD166 in the
clinical success group. CD166 has been used as a marker
to identify mesenchymal progenitor cells in cartilage [40,
41]. The expression of CD166 has been reported to be
upregulated upon dedifferentiation [42], and others have
observed expression changes also during redifferentiation
[43]. However, there are no records of the predictive po-
tential of CD166 in clinical outcomes. Our findings on
CD166 represent an interesting lead with clinical rele-
vance that deserves further investigation.
Several studies have implied that integrins, a group of
cell surface receptors facilitating chondrocyte-matrix
Fig. 6 Comparative global protein expression analysis by LC-MS/MS between chondrocyte cultures associated with different chondrogenesis and
clinical outcomes. a Volcano plot represents the expression of proteins in low chondrogenic samples (Group B) compared to high chondrogenic
samples (Group A). Proteins underwent greater fold change, and lower p-value in the comparison are plotted further away from zero on X-axis
and Y-axis, respectively. The red dots show significantly down-regulated proteins (FDR < 0.05) in chondrogenic group B. b Heat map showing the
differentially expressed proteins when comparing chondrogenic groups. c Validation of P4HA1 protein expression by western blot. ImageJ
software was used for relative quantification of P4HA1 (61 kDa) protein band to the loading control β-Actin (45 kDa). d Volcano plot represents
the expression of proteins in clinical failure group compared to clinical success group. Significance level, p (*) < 0.05
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crosstalk, are central players in differentiation and chon-
drogenesis [20, 44]. Grogan et al. suggested ITGA3 as a
marker for high chondrogenic potential, and also
showed upregulation of ITGA5 and ITGA6 in chondro-
genesis [20]. Another study investigating the effect of
blocking ITGA1, ITGA5 and ITGB1 on chondrogenesis,
reported early chondrogenesis was only inhibited by
blocking ITGB1 [45]. Unlike their observations, we
found ITGA1 and ITGB1 expression associated with
high chondrogenesis, but no correlations of other integ-
rin alpha units with chondrogenesis or clinical outcomes
(Figs. 4 and 5). COMP, a matrix molecule, has previously
been investigated as a potential biomarker. Unlike
Wright et al. who found no correlation between COMP
protein level in synovial fluid and clinical outcome [13],
we found that the gene expression of COMP was signifi-
cantly upregulated in the clinical failure group. Collect-
ively, these observations suggest that markers associated
with chondrogenesis of cells have limited or no value in
clinical settings. Lastly, our gene expression analyses re-
vealed significant upregulation of TGFBR3 gene in the
poor chondrogenic group. We have not found any previ-
ous studies on TGFBR3 in relation to chondrogenesis.
However, an upregulation upon dedifferentiation of
chondrocytes has been suggested [46]. The clinical rele-
vance of this finding is still uncertain.
The global proteomic approach to search for poten-
tial new biomarkers in cell-associated material re-
vealed no differences between clinical success and
failure group (Fig. 6). Similar observations were made
by Stenberg et al. using global transcriptomics to
compare clinical success and failure groups [17]. We
found all subunits of the enzyme prolyl-4-hydroxylase
among the seven proteins that were downregulated in
the low chondrogenic group. Previous studies have re-
ported gene and protein expression of P4HA1,
P4HA2 and P4HB in human chondrocytes [47] and
showed that they were induced by hypoxia. The role
of P4HA1 in chondrogenesis is not yet defined, but
given the critical role of this enzyme in the triple
helix formation of newly formed collagens, our results
suggest that P4HA1 (FDR < 0.01) could represent a
promising biomarker to predict the cells with superior
in vitro chondrogenic potential.
There are limitations of this study that need to be
addressed. The relatively low number of patients in-
cluded in the study may not give sufficient statistical
power to find differences between the experimental
groups. Hence the findings unveiled in the present
study should be validated in larger cohorts. Addition-
ally, in our chondrogenic assay, we have obviated the
use of mechanical stimulation. Although being a dis-
pensable factor to achieve redifferentiation of chon-
drocytes in vitro, the use of mechanical stimulation
or longer in vitro culture has been shown to advance
the maturation of neocartilage and entail superior
redifferentiation potential [48, 49]. The use of a more
advanced model incorporating mechanical stimulation
could have produced a different result regarding the
correlation between the in vitro chondrogenic poten-
tial and clinical outcome. Moreover, the clinical data
represent short-term (two-year follow up) outcomes.
A long-term follow-up in which the number of fail-
ures could increase might provide different scenarios
[7]. We used Lysholm scores with a cut-off of 65 at
two years postoperative to discern between clinical
success and failure. However, we do not have records
of factors that might have affected the healing process
after ACI including lifestyle, impaired joint homeosta-
sis, and concurrent use of medications. Finally, we do
not have postoperative biopsies of the repair tissue so
we are unable to make direct comparisons between
the in vitro chondrogenic potential and the quality of
the repaired tissue in vivo, which as mentioned earl-
ier, may not necessarily have a direct correlation with
clinical outcomes.
Conclusions
This is the first study evaluating the in vitro chondrogenic
potential of donor-matched chondrocytes and ACI clinical
outcomes. The study shows that the cartilage-forming
capacity of cells in vitro does not correlate with clinical
outcomes for ACI. Additionally, the results reveal dispar-
ities between predictive markers of chondrogenesis and
predictive markers of clinical outcomes. Furthermore, we
provide insights into novel predictive biomarkers for
chondrogenesis and clinical outcomes. The data presented
in this study needs to be validated in a larger cohort of pa-
tients. However, our findings do not support the use of in
vitro chondrogenic potential or molecular markers for
chondrogenesis as predictive tools to be used in patient
stratification for ACI.
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the nuclei counterstained with Sirius red. (TIF 33702 kb)
Additional file 2: Figure S2. Comparison of selected genes between
chondrogenic groups. Analysis of genes of interest by qPCR revealed
their relative expression in the high (n = 8) and low (n = 5) chondrogenic
groups. Plotted values represent each donor, and the error bar represents
standard deviation. Significance level, p (*) < 0.05. (TIF 7762 kb)
Additional file 3: Figure S3. Comparison of selected genes between
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standard deviation. Significance level, p (*) < 0.05. (TIF 7824 kb)
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